繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 激素类 >> 培维索孟注射液|Somavert(Pegvisomant Injection)

培维索孟注射液|Somavert(Pegvisomant Injection)

2012-06-29 09:27:12  作者:新特药房  来源:中国新特药网天津分站  浏览次数:482  文字大小:【】【】【
简介: 英文药名: Somavert(Pegvisomant Injection) 中文药名: 索玛沃(培维索孟注射液) 品牌药生产厂家: Pfizer 药物剂型 注射剂:10mg;15mg;20mg。 药品介绍 欧盟批准somavert用于治疗肢端肥大欧盟 ...

英文药名: Somavert(Pegvisomant Injection)

中文药名: 索玛沃(培维索孟注射液)

生产厂家: Pfizer
药品介绍
欧盟已批准Somavert(pegvisomant粉末及溶媒)用于肢端肥大症的治疗。治疗对象为对手术疗法或是放疗无足够响应以及那些应用生长抑素类似物但体内IGF-I水平不能恢复正常的患者以及对生长抑素无法耐受的患者。
肢端肥大症是由体内分泌过多的生长激素引起的一种严重病变,生长激素的过多分泌多数是由垂体瘤引起的,它也能导致第二激素IGF-1(类胰岛素生长因子-1)的过量产生,由此引起身体一些残废症状及长期的与此病相关的各种健康问题。
Somavert为第一类生长因子受体拮抗剂,它能特异性地抑制生长激素对身体的影响,一项随机临床试验,两项长期开放标签、调整剂量的临床试验对该药进行了研究。长期试验中,该药能使90%的患者恢复正常的IGF-1水平。 IGF-1水平的正常是治疗肢端肥大症的一个基本目标。目前该药正在接受FDA的审评。
Somavert的禁忌症为对pegvisomant或其中任一种赋形剂过敏的患者,临床试验中,最常见的不良反应是至少有5%的病人注射部位不适,出汗,头痛,浑身无力。建议在治疗开始的前六个月,要对患者的肝功能进行监控。
药理作用
本品为生长激素(growth hormone,GH)受体拮抗剂。生长激素受生长激素释放激素(GHRH)和生长抑素(SMS)调节,循环中的生长激素与周围组织(如肌肉、肝脏、骨组织)中的生长激素受体(GHR)结合导致胰岛素样生长因子-1的分泌,对靶组织产生生长刺激作用。本品为GH类似物,能与GHR1的位点结合,从而抑制GH与GHR的结合,使肢端肥大症(也称巨人症)患者的胰岛素样生长因子-1的浓度达到正常水平。
药动学
皮下注射本品后33~77h血药浓度达高峰,与静注10mg相比,皮下注射20mg的平均吸收率为57%。表观分布容积为7L,表示本品无组织分布。皮下注射后,本品的峰浓度(Cmax)和药时曲线下面积(AUC)不随剂量成比例增加。每天皮下注射本品10mg、15mg、20mg,12周后血浆药物浓度分别为(6.6±1.33)μg/ml、(16.0±2.2)μg/ml、(27.0±3.1)μg/ml。本品分子与聚乙二醇通过共价键结合,降低了清除率。每天皮下注射本品10~20mg,多次给药后平均清除率为28~36ml/h,清除率随体重的增加而增加。单剂量或多剂量给药后平均半衰期为6天,给药96h后,尿中回收率不足1%。
适应证
用于降低肢端肥大症患者的胰岛素样生长因子-1浓度。
禁忌证
对本品过敏者禁用。
注意事项
1.本品生殖毒性分级为B,孕妇慎用。尚不知本品是否经乳汁分泌,哺乳期妇女慎用。老年人应慎用,并从小剂量开始。
2.可能引起垂体瘤生长,治疗过程中,必须密切关注垂体瘤的体积。
3.用药期间应定期监测肝功能。
4.本品可使肢端肥大症患者中低水平的TC、LDL、脂蛋白B、高脂蛋白A恢复正常。
5.本品过量可引起疲乏加重,出现药物过量后应停止用药,直到IGF-1达到或超过正常水平。
6.2~8℃冰箱保存,禁止冷冻。溶解后的溶液6h内用完。
不良反应
一般能很好耐受,少数患者垂体瘤出现进展性增长,个别患者肝功能检测出现丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)中等程度升高,一些患者发现有抗GH的中和抗体,但在治疗过程中这些抗体似乎没有影响药物的作用。
其他不良反应如下
1.全身:感染(包括上呼吸道感染、水疱、耳部感染)、疼痛、注射部位反应、意外伤害、背痛、流感样症状、胸痛。
2.消化系统:肝功能异常、腹泻、恶心。
3.神经系统:头晕、感觉异常。
4.代谢:外周水肿。
5.心血管系统:高血压。
6.呼吸系统:鼻窦炎。
用法用量
皮下注射:负荷剂量40mg。维持剂量从10mg开始,每4~6周检测血浆IGF-1浓度,如果IGF-1浓度高于正常值,本品剂量增加5mg,直到IGF-1浓度达到正常范围,肢端肥大症状得到缓解。最大维持剂量不得超过每天30mg。
药物相应作用
1,生长激素能通过降低胰岛素的敏感性而降低胰岛素的糖代谢作用,本品为生长激素受体拮抗剂,可能提高胰岛素的敏感性,与胰岛素或口服降血糖药合用应适当降低降血糖药剂量。
2.本品与罂粟碱类药物合用需增加剂量。
厂家:德国Pfizer
包装规格
1针/盒x20mg:
30针盒x10mg:
30针盒x15mg:
30针盒x20mg:


SOMAVERT 10mg, 15mg, 20mg, 25mg and 30mg powder and solvent for solution for injection
1. Name of the medicinal product
SOMAVERT 10 mg powder and solvent for solution for injection.
SOMAVERT 15 mg Powder and solvent for solution for injection.
SOMAVERT 20 mg Powder and solvent for solution for injection.
SOMAVERT 25 mg Powder and solvent for solution for injection.
SOMAVERT 30 mg Powder and solvent for solution for injection.
2. Qualitative and quantitative composition

Presentations

SOMAVERT 10mg

Each vial contains 10 mg of pegvisomant.

After reconstitution, 1 mL of solution contains 10 mg pegvisomant.

SOMAVERT 15mg

Each vial contains 15 mg of pegvisomant.

After reconstitution, 1 mL of solution contains 15 mg pegvisomant.

SOMAVERT 20mg

Each vial contains 20 mg of pegvisomant.

After reconstitution, 1 mL of solution contains 20 mg pegvisomant.

SOMAVERT 25mg

Each vial contains 25 mg of pegvisomant.

After reconstitution, 1 mL of solution contains 25 mg pegvisomant.

SOMAVERT 30mg

Each vial contains 30 mg of pegvisomant.

After reconstitution, 1 mL of solution contains 30 mg pegvisomant

Pegvisomant is produced in Escherichia coli cells by recombinant DNA technology.
Excipient(s) with known effect:
The medicinal product contains 0.4 mg of sodium in SOMAVERT 10 mg, 15 mg and 20 mg.
The medicinal product contains 0.5 mg of sodium in SOMAVERT 25 mg.
The medicinal product contains 0.6 mg of sodium in SOMAVERT 30 mg.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Powder and solvent for solution for injection.
The powder is white to slightly off-white.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated.
4.2 Posology and method of administration
Treatment should be initiated under the supervision of a physician experienced in the treatment of acromegaly.
Posology
A loading dose of 80 mg pegvisomant should be administered subcutaneously under medical supervision. Following this, SOMAVERT 10 mg reconstituted in 1 mL of solvent should be administered once daily as a subcutaneous injection.
Dose adjustments should be based on serum IGF-I levels. Serum IGF-I concentrations should be measured every four to six weeks and appropriate dose adjustments made in increments of 5 mg/day in order to maintain the serum IGF-I concentration within the age-adjusted normal range and to maintain an optimal therapeutic response.
The maximum dose should not exceed 30 mg/day.
For the different dose regimens the following strengths are available: SOMAVERT 10 mg, SOMAVERT 15 mg, SOMAVERT 20 mg, SOMAVERT 25 mg and SOMAVERT 30 mg.
Paediatric population
The safety and efficacy of SOMAVERT in children aged 0 to 17 years have not been established. No data are available.
Elderly
No dose adjustment is required.
Patients with hepatic or renal impairment
The safety and efficacy of SOMAVERT in patients with renal or hepatic insufficiency has not been established.
Method of administration
Pegvisomant should be administered by subcutaneous injection.
The site of injection should be rotated daily to help prevent lipohypertrophy.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Growth hormone-secreting tumours
Growth hormone-secreting pituitary tumours may sometimes expand, causing serious complications (for example, visual field defects). Treatment by pegvisomant does not reduce tumour size. All patients with these tumours should be carefully monitored in order to avoid any eventual progression in tumour size under treatment.
Serum IGF-1 monitoring
Pegvisomant is a potent antagonist of growth hormone action. A growth hormone deficient state may result from administration of this medicine, despite the presence of elevated serum growth hormone levels. Serum IGF-I concentrations should be monitored and maintained within the age-adjusted normal range by adjustment of the pegvisomant dose.
ALT or AST elevations
Serum concentrations of alanine aminotransferase (ALT) and aspartate transaminase (AST) should be monitored at four to six week intervals for the first six months of treatment with pegvisomant, or at any time in patients exhibiting symptoms suggestive of hepatitis. Evidence of obstructive biliary tract disease should be ruled out in patients with elevations of ALT and AST or in patients with a prior history of treatment with any somatostatin analogue. Administration of pegvisomant should be discontinued if signs of liver disease persist.
Hypoglycaemia
The study conducted with pegvisomant in diabetic patients treated either by insulin or by oral hypoglycaemic medicinal products revealed the risk of hypoglycaemia in this population. Therefore, in acromegalic patients with diabetes mellitus, doses of insulin or hypoglycaemic medicinal products may need to be decreased (see also section 4.5).
Increased fertility
The therapeutic benefits of a reduction in IGF-I concentration which results in improvement of the patient's clinical condition could potentially increase fertility in female patients. Patients should be advised to use adequate contraception if necessary. Pegvisomant is not recommended during pregnancy (see also section 4.6).
4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed. It should be considered whether to continue treatment with somatostatin analogues. The use of this medicine in combination with other medicinal products for the treatment of acromegaly has not been extensively investigated.
Patients receiving insulin or oral hypoglycaemic medicinal products may require dose reduction of these active substances due to the effect of pegvisomant on insulin sensitivity (see section 4.4).
Pegvisomant has significant structural similarity to growth hormone which causes it to cross-react in commercially available growth hormone assays. Since serum concentrations of therapeutically-effective doses of this medicine are generally 100 to 1000 times higher than the actual serum growth hormone concentrations seen in acromegalics, measurements of serum growth hormone concentrations will be spuriously reported in commercially available growth hormone assays. Pegvisomant treatment should therefore not be monitored or adjusted based on serum growth hormone concentrations reported from these assays.
4.6. Fertility, pregnancy and lactation
Women of childbearing potential
See section 4.4.
Pregnancy
For pegvisomant no clinical data on exposed pregnancies are available.
Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).The potential risk for humans is unknown.
SOMAVERT should not be used during pregnancy unless clearly necessary (see also section 4.4).
Breast-feeding
The excretion of pegvisomant in breast milk has not been studied in animals. Clinical data are too limited (one reported case) to draw any conclusion on the excretion of pegvisomant in human breast milk. Therefore, pegvisomant should not be used in breast-feeding women. However, breast-feeding may be continued if this medicine is discontinued: this decision should take into account the benefit of pegvisomant therapy to the mother and the benefit of breast-feeding to the child.
Fertility
For pegvisomant no data on fertility are available.
4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed.
4.8 Undesirable effects
Summary of the safety profile
The list below contains adverse reactions seen in clinical trials with SOMAVERT.
In clinical studies, for patients treated with pegvisomant (n=160), the majority of adverse reactions to pegvisomant were of mild to moderate intensity, of limited duration and did not require discontinuation of treatment.
The most commonly reported adverse reactions considered related to pegvisomant occurring in ≥ 5% of patients with acromegaly during the clinical trials were injection site reactions 11%, hyperhidrosis 7%, headache 6% and asthenia 6%.
Tabulated list of adverse reactions
The list below contains adverse reactions seen in clinical trials or that were spontaneously reported, classified by system organ class and frequency. Reports from post-marketing experience are included in italics.
Adverse reactions are listed according to the following categories:
Common: ≥1/100 to <1/10
Uncommon: ≥1/1,000 to <1/100
Not known (cannot be estimated from the available data)
Blood and lymphatic system disorders:
Uncommon: thrombocytopenia, leucopenia, leucocytosis, haemorrhagic diathesis
Metabolism and nutrition disorders:
Common: hypercholesterolemia, weight gain, hyperglycaemia, hunger
Uncommon: hypertriglyceridemia, hypoglycaemia
Immune system disorders:
Not known: systemic hypersensitivity reactions*
Psychiatric disorders:
Common: abnormal dreams, sleep disorder
Uncommon: anger, apathy, confusion, increased libido, panic attack, short term memory loss
Nervous system disorders:
Common: headache, dizziness, somnolence, tremor
Uncommon: hypoesthesia, dysgeusia, migraine, narcolepsy
Eye disorders:
Uncommon: asthenopia, eye pain
Ear and labyrinth disorders:
Uncommon: Meniere's disease
Cardiac disorders:
Common: oedema peripheral
Vascular disorders
Common: hypertension
Respiratory, thoracic and mediastinal disorders:
Uncommon: dyspnoea
Gastrointestinal disorders:
Common: diarrhoea, constipation, nausea, vomiting, abdominal distension, dyspepsia, flatulence
Uncommon: dry mouth, hemorrhoids, salivary hypersecretion, tooth disorder
Hepatobiliary disorders:
Common abnormal liver function tests (e.g. transaminase elevation) (see section 4.4)
Skin and subcutaneous tissue disorders:
Common: hyperhidrosis, pruritus, rash
Uncommon: face oedema, dry skin, contusion, increased tendency to bruise, night sweats
Musculoskeletal and connective tissue disorders:
Common: arthralgia, myalgia
Uncommon: arthritis
Renal and urinary disorders:
Uncommon: haematuria, proteinuria, polyuria, renal impairment
General disorders and administration site conditions:
Common: influenza-like illness, fatigue, injection site bruising or bleeding, injection site reaction (including injection site hypersensitivity), injection site hypertrophy (e.g. lipohypertrophy)*, asthenia
Uncommon: pyrexia, feeling abnormal, impaired healing
*see Description of selected adverse reactions below.
Description of selected adverse reactions
Most injection site reactions characterised as localised erythemas and soreness, spontaneously resolved with local symptomatic treatment, while pegvisomant therapy continued. Occurrence of injection site hypertrophy has been observed, including lipohypertrophy.
The development of isolated low-titre anti-growth hormone antibodies was observed in 16.9% of patients treated with pegvisomant. The clinical significance of these antibodies is unknown.
Systemic hypersensitivity reactions including anaphylactic/anaphylactoid reactions, laryngospasm, angioedema, generalized skin reactions (rash, erythema, pruritus, urticaria).have been reported in post marketing use. Some patients required hospitalization. Upon re-administration, symptoms did not re-occur in all patients.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
United Kingdom
Yellow Card Scheme website:
www.mhra.gov.uk/yellowcard
Ireland
HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971
Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.
4.9 Overdose
There is limited experience of overdose with pegvisomant. In the one reported incident of acute overdose, where 80 mg/day was administered for 7 days, the patient experienced a slight increase in fatigue and dry mouth. In the week following discontinuation of treatment the adverse reactions noted were: insomnia, increased fatigue, oedema peripheral, tremor, and weight gain. Two weeks after stopping treatment, leukocytosis and moderate bleeding from injection and vein puncture sites was observed which were considered possibly related to pegvisomant.
In cases of overdose, administration of this medicine should be discontinued and not resumed until IGF-I levels return to within or above the normal range.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Other anterior pituitary lobe hormones and analogues, ATC code: H01AX01.
Mechanism of action
Pegvisomant is an analogue of human growth hormone that has been genetically modified to be a growth hormone receptor antagonist. Pegvisomant binds to growth hormone receptors on cell surfaces, where it blocks growth hormone binding, and thus interferes with intracellular growth hormone signal transduction. Pegvisomant is highly selective for the GH receptor, and does not cross-react with other cytokine receptors, including prolactin.
Pharmacodynamic effects
Inhibition of growth hormone action with pegvisomant leads to decreased serum concentrations of insulin-like growth factor-I (IGF-I), as well as other growth hormone-responsive serum proteins such as free IGF-I, the acid-labile subunit of IGF-I (ALS), and insulin-like growth factor binding protein-3 (IGFBP-3).
Clinical efficacy and safety
Acromegalic patients (n=112) have been treated in a 12-week, randomised, double-blind, multicentre study comparing placebo and pegvisomant. Dose-dependent, statistically significant reductions in mean IGF-I (p<0.0001), free IGF-I (p<0.05), IGFBP-3 (p<0.05) and ALS (p<0.05) were observed at all post-baseline visits in the pegvisomant treatment groups. The serum IGF-1 was normalised at the end of the study (week 12) in 9.7%, 38.5%, 75% and 82% of subjects treated with placebo, 10 mg/day, 15 mg/day or 20 mg/day pegvisomant respectively.
Statistically significant differences from placebo (p<0.05) were observed for improvements in the total signs and symptoms score for all dose groups compared to placebo.
A cohort of 38 acromegalic subjects has been followed in a long-term, open-label, dose-titration study for at least 12 consecutive months of daily dosing with pegvisomant (mean = 55 weeks). The mean IGF-I concentration in this cohort fell from 917 ng/mL to 299 ng/mL on pegvisomant, with 92% achieving a normal (age-adjusted) IGF-I concentration.
5.2 Pharmacokinetic properties
Absorption
Absorption of pegvisomant following subcutaneous administration is slow and prolonged, and peak serum pegvisomant concentrations are not generally attained until 33-77 hours after administration. The mean extent of absorption of a subcutaneous dose was 57% relative to an intravenous dose.
Distribution
The apparent volume of distribution of pegvisomant is relatively small (7-12 L).
Biotransformation
The metabolism of pegvisomant has not been studied.
Elimination
The mean total body systemic clearance of pegvisomant following multiple doses is estimated to be 28 mL/h for subcutaneous doses ranging from 10 to 20 mg/day. Renal clearance of pegvisomant is negligible and accounts for less than 1% of total body clearance. Pegvisomant is slowly eliminated from serum, with mean estimates of half-life generally ranging from 74 to 172 hours following either single or multiple-doses.
Linearity/non-linearity
After single subcutaneous pegvisomant administration no linearity is observed with rising doses of 10, 15 or 20 mg. Approximately linear pharmacokinetics is observed at steady state in the population pharmacokinetic studies. The data from 145 patients in two long-term studies who received daily doses of 10, 15, or 20 mg, demonstrate pegvisomant mean serum concentrations (± SD) of approximately 8800 ± 6300, 13200 ± 8000 and 15600 ± 10300 ng/mL, respectively.
The pharmacokinetics of pegvisomant are similar in normal healthy volunteers and acromegaly patients, although heavier individuals tend to have a higher total body clearance of pegvisomant than lighter individuals, and may thus require greater doses of pegvisomant.
5.3 Preclinical safety data
Non-clinical data revealed no special hazard for humans based on studies of repeated dose toxicity in rat and monkey. However, due to the marked pharmacological response in monkey, systemic exposures higher than those achieved in patients at therapeutic doses have not been studied. Except for one segment II test in the rabbit, no other reproductive toxicity studies were conducted.
Malignant fibrous histiocytomas associated with fibrosis and histiocytic inflammation were observed at injection sites in males in the rat carcinogenicity study at exposure levels equivalent to three times the human exposure based on mean plasma concentrations in two long-term studies at a daily dose of 30 mg. The relevance of this response for humans is currently unknown.
6. Pharmaceutical particulars
6.1 List of excipients
Powder:
Glycine
Mannitol (E421)
Disodium phosphate anhydrous
Sodium dihydrogen phosphate monohydrate
Solvent:
Water for Injections
6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
6.3 Shelf life
3 years.
After reconstitution, the product should be used immediately.
6.4 Special precautions for storage
Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the vial in the outer carton in order to protect from light.
After reconstitution:
For storage conditions after reconstitution of the medicinal product, see section 6.3.
6.5 Nature and contents of container
Vial (type I glass) with a stopper (butyl rubber). The colour of the protective plastic cap is specific to the strength of the product.
The powder vial contains 10 mg, 15 mg, 20 mg, 25 mg or 30 mg pegvisomant.
The solvent vial contains 8 mL of water for injections.
Pack sizes of 1 and 30. Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
The powder should be reconstituted in 1 mL solvent.
Add solvent to vial with powder for injection. Gently dissolve the powder with a slow, swirling motion. Do not shake vigorously, as this might cause denaturation of the active substance.
After reconstitution, if the solution is cloudy or contains particulate matter, the product must be discarded.
For single use only. Any unused product or waste material should be disposed of in accordance with local requirements.
7. Marketing authorisation holder
Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom
8. Marketing authorisation number(s)
EU/1/02/240/001 - SOMAVERT 10 mg; pack size 30 vials
EU/1/02/240/002 - SOMAVERT 15 mg; pack size 30 vials
EU/1/02/240/003 - SOMAVERT 20 mg; pack size 30 vials
EU/1/02/240/004 - SOMAVERT 20 mg; pack size 1 vial
EU/1/02/240/009 - SOMAVERT 25 mg; pack size 1 vial
EU/1/02/240/010 - SOMAVERT 25 mg; pack size 30 vials
EU/1/02/240/011 - SOMAVERT 30 mg; pack size 1 vial
EU/1/02/240/012 - SOMAVERT 30 mg; pack size 30 vials
9. Date of first authorisation/renewal of the authorisation
Date of first authorization: 13/11/2002
Date of latest renewal: 20/09/2007
10. Date of revision of the text
July 2015


FDA批准Somavert(Pegvisomant)为肢端肥大症治疗药
2003年,FDA批准Somavert用于那些无法通过手术或其他治疗手段包括放疗受益的患者。  
欧盟在去年就批准了Somavert用于治疗肢端肥大-即巨人症。公司称,Somavert将会是治疗肢端肥大这类病症的金标准药物。  
典型肢端肥大症主要是由脑垂体内的肿瘤引起的,肿瘤刺激着生长激素的产生,而这又导致另一种生长激素IGF-I的过量产生,最终引发全身性疾病。  
症状出现时间典型是在30-50岁之间,包括面部特征变得粗糙,手脚及指甲变大,关节弯曲,10%的患者在童年既有症状出现,一些患者身高甚至超过7英尺。  
Somavert为第一种生长激素受体拮抗剂,可在生长激素被分泌后抑制其发挥功能,而诺华公司的药物Sandostatin则是抑制脑垂体实际产生的生长激素的数量。  
临床试验显示,Somavert可以使90%的用药患者症状得到控制,IGF-I水平恢复常规。

责任编辑:admin


相关文章
VALSARTAN TABLETS(缬沙坦片)
Zofran Injection(盐酸恩丹西酮注射剂)
Irribow OD Tablets(Ramosetron Hydrochloride)盐酸雷莫司琼崩解片
腹泻型肠易激综合征新配方Irribow OD片获日本批准
美国FDA批准Natpara注射液为治疗甲状旁腺功能减退新药
Somatuline for s.c. Injection(醋酸兰瑞肽皮下注射剂)
阿瑞吡坦胶囊|EMEND(Aprepitant CAP)
NORDITROPIN CARTRIDGES(生长激素[rDNA来源]注射剂/预填充笔)
索玛沃(培维索孟注射液)|Somavert(Pegvisomant Injection)
培维索孟注射液|Somavert(Pegvisomant Injection)
 

最新文章

更多

· Norditropin Simplexx I...
· 生长激素注射剂|Saizen(...
· REGPARA TABLETS(Cinac...
· Signifor(Pasireotide s...
· Sandostatin(Octreotide...
· SOL-MELCORT for inject...
· hCRH TANABE Injection(...
· Gonal-f RFF(follitropi...
· Sandostatin LAR kit(醋...
· Somatuline for s.c. In...

推荐文章

更多

· Norditropin Simplexx I...
· 生长激素注射剂|Saizen(...
· REGPARA TABLETS(Cinac...
· Signifor(Pasireotide s...
· Sandostatin(Octreotide...
· SOL-MELCORT for inject...
· hCRH TANABE Injection(...
· Gonal-f RFF(follitropi...
· Sandostatin LAR kit(醋...
· Somatuline for s.c. In...

热点文章

更多

· 生长激素注射剂|Saizen(...
· Norditropin Simplexx I...